Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005493 · ClinicalTrials.gov registry record · Phase 1
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT06005493: Recruiting Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.
NCT06005493 is a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 280 participants, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06005493, a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Conditions Studied
Interventions
- DRUG AZD5863
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Beijing
- Research Site - Shandong
- Research Site - Toulouse
- Research Site - Villejuif
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Kōtoku
- Research Site - Amsterdam
- Research Site - Groningen
- Research Site - Rotterdam
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Kaohsiung City
- Research Site - Tainan
Florida
- Research Site - Jacksonville
Minnesota
- Research Site - Rochester
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2027-07-16 |
| Phase | Phase 1 |
What NCT06005493 shows while recruiting
NCT06005493 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (12% lower).
The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD5863 is the first listed.
NCT06005493 names 20 study sites across 4 states, led by Other, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06005493 about?
NCT06005493 is a clinical study titled "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors". This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
What is the current status of trial NCT06005493?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2023-07-11. Estimated completion is 2027-07-16.
What conditions does trial NCT06005493 study?
This clinical trial studies the following conditions: Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06005493?
The interventions under investigation include: AZD5863 (DRUG).
Who is sponsoring clinical trial NCT06005493?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06005493 being conducted?
This trial has 20 study locations across Florida, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06005493's enrollment target sits among peer trials
280 41st of 153 higher than 112 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI